title: Novel dendritic cell-based vaccination in late stage melanoma.
abstract: Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play an important role in stimulating an immune response of both CD4(+) T helper cells and CD8(+) cytotoxic T lymphocytes (CTLs). As such, DCs have been studied extensively in cancer immunotherapy for their capability to induce a specific anti-tumor response when loaded with tumor antigens. However, when the most relevant antigens of a tumor remain to be identified, alternative approaches are required. Formation of a dentritoma, a fused DC and tumor cells hybrid, is one strategy. Although initial studies of these hybrid cells are promising, several limitations interfere with its clinical and commercial application. Here we present early experience in clinical trials and an alternative approach to manufacturing this DC/tumor cell hybrid for use in the treatment of late stage and metastatic melanoma.
authors.affiliation: a San Antonio Military Medical Center; Department of General Surgery ; San Antonio , TX USA.
authors.forename: Erika J
authors.initials: EJ
authors.lastname: Schneble
authors.forename: Xianzhong
authors.initials: X
authors.lastname: Yu
authors.forename: T E
authors.initials: TE
authors.lastname: Wagner
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002459:Cell Fusion; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D006822:Hybrid Cells / Q000276:immunology* / Q000637:transplantation; D016219:Immunotherapy, Adoptive / Q000379:methods*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D000074324:Ipilimumab; D008545:Melanoma / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C508594:IL2 protein, human; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D000074324:Ipilimumab; D011994:Recombinant Proteins
keywords: adjuvant; cancer vaccine; dendritic cell; melanoma